PROMIS NEUROSCIENCES INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $708.47K.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $0.00.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for fiscal 2024 was $190.27K, a 98.93% decline from fiscal 2023.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for fiscal 2023 was $17.75M, a 256.74% increase from fiscal 2022.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for fiscal 2022 was $4.97M, a 68.65% decline from fiscal 2021.
- PROMIS NEUROSCIENCES INC. stock issued during period, value, new issues for fiscal 2021 was $15.87M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $708.47K 10-Q · filed 2025-11-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $190.27K 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $190.27K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $17.94M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $190.27K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $17.75M 10-K · filed 2025-03-31 |
| 2023-09-30 | $17.75M 10-Q · filed 2023-11-14 | |
| 2022-12-31 | $4.97M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $445.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $15.87M 10-K · filed 2023-03-08 |
| 2021-09-30 | $15.87M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |